86 related articles for article (PubMed ID: 22247028)
1. [Genetic polymorphisms as new predictive factors for successful treatment of chronic hepatitis C].
Válková I; Kristian P; Schréter I; Habalová V
Klin Mikrobiol Infekc Lek; 2011 Dec; 17(6):190-3. PubMed ID: 22247028
[TBL] [Abstract][Full Text] [Related]
2. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
3. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
Hai H; Tamori A; Enomoto M; Morikawa H; Uchida-Kobayashi S; Fujii H; Hagihara A; Kawamura E; Thuy le TT; Tanaka Y; Kawada N
J Gastroenterol Hepatol; 2014 Jan; 29(1):201-7. PubMed ID: 23980585
[TBL] [Abstract][Full Text] [Related]
4. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
[TBL] [Abstract][Full Text] [Related]
5. Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C.
Matsushita H; Ikeda F; Iwasaki Y; Seki H; Nanba S; Takeuchi Y; Moritou Y; Yasunaka T; Onishi H; Miyake Y; Takaki A; Nouso K; Yamamoto K
J Gastroenterol Hepatol; 2014 Feb; 29(2):337-43. PubMed ID: 23869873
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
[TBL] [Abstract][Full Text] [Related]
7. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
J Viral Hepat; 2013 Jan; 20(1):59-64. PubMed ID: 23231085
[TBL] [Abstract][Full Text] [Related]
8. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
Sakamoto N; Nakagawa M; Tanaka Y; Sekine-Osajima Y; Ueyama M; Kurosaki M; Nishida N; Tamori A; Yuki NS; Itsui Y; Azuma S; Kakinuma S; Hige S; Itoh Y; Tanaka E; Hiasa Y; Izumi N; Tokunaga K; Mizokami M; Watanabe M;
J Med Virol; 2011 May; 83(5):871-8. PubMed ID: 21360545
[TBL] [Abstract][Full Text] [Related]
9. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Chevaliez S; Hézode C; Soulier A; Costes B; Bouvier-Alias M; Rouanet S; Foucher J; Bronowicki JP; Tran A; Rosa I; Mathurin P; Alric L; Leroy V; Couzigou P; Mallat A; Charaf-Eddine M; Babany G; Pawlotsky JM
Gastroenterology; 2011 Jul; 141(1):119-27. PubMed ID: 21439960
[TBL] [Abstract][Full Text] [Related]
10. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
[TBL] [Abstract][Full Text] [Related]
12. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
[TBL] [Abstract][Full Text] [Related]
13. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
[TBL] [Abstract][Full Text] [Related]
14. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
15. Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.
Waldenström J; Färkkilä M; Rembeck K; Norkrans G; Langeland N; Mørch K; Pedersen C; Rauning Buhl M; Nieminen U; Nuutinen H; Alsiö Å; Holmström L; Jungnelius R; Lund K; Rubensson A; Torell E; Westin J; Lagging M
Scand J Gastroenterol; 2016 Mar; 51(3):337-43. PubMed ID: 26418670
[TBL] [Abstract][Full Text] [Related]
16. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
17. High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C.
Orlent H; Hansen B; Janssen HL; De Knegt RJ
Dig Liver Dis; 2015 Jan; 47(1):87-8. PubMed ID: 25308611
[No Abstract] [Full Text] [Related]
18. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
Abe H; Hayes CN; Ochi H; Maekawa T; Tsuge M; Miki D; Mitsui F; Hiraga N; Imamura M; Takahashi S; Kubo M; Nakamura Y; Chayama K
J Hepatol; 2011 Jun; 54(6):1094-101. PubMed ID: 21145800
[TBL] [Abstract][Full Text] [Related]
19. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
